TMAVA, a Metabolite of Intestinal Microbes, Is Increased in Plasma From Patients With Liver Steatosis, Inhibits γ-Butyrobetaine Hydroxylase, and Exacerbates Fatty Liver in Mice
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND & AIMS Non-alcoholic fatty liver disease is characterized by excessive hepatic accumulation of triglycerides. We aimed to identify metabolites that differ in liver tissues of patients with liver steatosis vs healthy individuals (controls) and investigate the mechanisms by which these might contribute to fatty liver in mice. METHODS We obtained blood samples from 15 patients with liver steatosis and 15 controls from a single center in China (discovery cohort). We performed untargeted liquid chromatography with mass spectrometry analysis of plasma to identify analytes associated with liver steatosis. We then performed targeted metabolomic analysis of blood samples from 2 independent cohorts of individuals who underwent annual health examinations in China (1157 subjects with or without diabetes and 766 subjects with or without liver steatosis; replication cohorts). We performed mass spectrometry analysis of plasma from C57BL/6J mice, germ-free, and mice given antibiotics. C57BL/6J mice with CRISPR-mediated disruption of the gene encoding γ-butyrobetaine hydroxylase (BBOX-knockout mice) were given 0.325% (m/v) N,N,N-trimethyl-5-aminovaleric acid (TMAVA) in their drinking water and placed on a 45% high fat diet (HFD) for 2 months. Plasma, liver tissues and fecal samples were collected; fecal samples were analyzed by 16S rRNA gene sequencing. Hepatic fatty acid oxidation (FAO) in liver tissues was determined by measuring liberation of 3H2O from [3H] palmitic acid. Liver tissues were analyzed by electron microscopy, to view mitochondria, and proteomic analyses. We used surface plasmon resonance analysis to quantify the affinity of TMAVA for BBOX. RESULTS Levels of TMAVA, believed to be a metabolite of intestinal microbes, were increased in plasma from subjects with liver steatosis compared with controls, in the discovery and replication cohorts. In 1 replication cohort, the odds ratio for fatty liver in subjects with increased liver levels of TMAVA was 1.82 (95% CI, 1.14-2.90; P=.012). Plasma from mice given antibiotics or germ-free mice had significant reductions in TMAVA compared with control mice. We found the intestinal bacteria Enterococcus faecalis and Pseudomonas aeruginosa to metabolize trimethyllysine to TMAVA; levels of trimethyllysine were significantly higher in plasma from patients with steatosis than controls. We found TMAVA to bind and inhibit BBOX, reducing synthesis of carnitine. Mice given TMAVA had alterations in their fecal microbiomes and reduced cold tolerance; their plasma and liver tissue had significant reductions in levels of carnitine and acyl-carnitine and their hepatocytes had reduced mitochondrial FAO, compared with mice given only on a HFD. Mice given TMAVA on a HFD developed liver steatosis, which was reduced by carnitine supplementation. BBOX-knockout mice had carnitine deficiency and decreased FAO, increasing uptake and liver accumulation of free fatty acids and exacerbating HFD-induced fatty liver. CONCLUSIONS Levels of TMAVA are increased in plasma from subjects with liver steatosis. In mice, intestinal microbes metabolize trimethyllysine to TMAVA, which reduces carnitine synthesis and FAO to promote steatosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
Wang, Z., Klipfell, E., Bennett, B. J., Koeth, R., Levison, B. S., DuGar, B., Feldstein, A. E., Britt, E. B., Fu, X., Chung, Y.-M., et al. (2011) · Nature · doi:10.1038/nature09922 · Cited by 5,597 · cited 2×
“The compelling story of trimethylamine-N-oxide (TMAO) provides a methodology to research the relationship between gut flora and cardiovascular diseases.(11,12) Specific metabolites and changes in the microbiota community and their pathophysiological contribution to NAFLD progression require more explicit characterizat…”
BackgroundMethodIntestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis
Koeth, R. A., Wang, Z., Levison, B. S., Buffa, J. A., Org, E., Sheehy, B. T., Britt, E. B., Fu, X., Wu, Y., Li, L., et al. (2013) · Nature Medicine · doi:10.1038/nm.3145 · Cited by 4,386
Metabolite profiles and the risk of developing diabetes
Wang, T. J., Larson, M. G., Vasan, R. S., Cheng, S., Rhee, E. P., McCabe, E., Lewis, G. D., Fox, C. S., Jacques, P. F., Fernandez, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2307 · Cited by 3,143 · cited 1×
“However, to date, many biomarkers only rest on population studies, while their associated biological mechanisms underlying the pathologies remain unknown.(10) The compelling story of trimethylamine-N-oxide (TMAO) provides a methodology to research the relationship between gut flora and cardiovascular diseases.”
BackgroundSelf-citationAlterations of the human gut microbiome in liver cirrhosis
Qin, N., Yang, F., Li, A., Prifti, E., Chen, Y., Shao, L., Guo, J., Le Chatelier, E., Yao, J., Wu, L., et al. (2014) · Nature · doi:10.1038/nature13568 · Cited by 2,177
Self-citationBoursier, J., Mueller, O., Barret, M., Machado, M., Fizanne, L., Araujo‐Perez, F., Guy, C. D., Seed, P. C., Rawls, J. F., David, L. A., et al. (2016) · Hepatology · doi:10.1002/hep.28356 · Cited by 1,483
Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase
Haemmerle, G., Lass, A., Zimmermann, R., Gorkiewicz, G., Meyer, C., Rozman, J., Heldmaier, G., Maier, R., Theussl, C., Eder, S., et al. (2006) · Science · doi:10.1126/science.1123965 · Cited by 1,375 · cited 1×
“This phenotype resembles that of b-adrenergic receptor–deficient mice(20) and adipose triglyceride lipase (ATGL)-deficient mice.(21) It suggests that insufficient amounts of FFAs are oxidized as an energy substrate for uncoupled mitochondrial respiration upon TMAVA treatment.”
BackgroundCause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis
Diehl, A. M., & Day, C. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1503519 · Cited by 1,283 · cited 1×
“Excessive lipids can lead to hepatocellular damage, including liver steatosis.(1) Mice given TMAVA have higher FFA levels in blood under nonfasting and fasting conditions (Figure 5G).”
BackgroundGut bacteria that prevent growth impairments transmitted by microbiota from malnourished children
Blanton, L. V., Charbonneau, M. R., Salih, T., Barratt, M. J., Venkatesh, S., Ilkaveya, O., Subramanian, S., Manary, M. J., Trehan, I., Jorgensen, J. M., et al. (2016) · Science · doi:10.1126/science.aad3311 · Cited by 735 · cited 1×
“Much of this evidence initially came from elegant experiments in mice showing that phenotypes could be altered through transfer of gut microbiota from obese animals to lean littermates.(7) Remarkably, fecal microbiota transplantation from a patient with severe alcoholic hepatitis into mice renders them more susceptibl…”
BackgroundDefective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis.
Pérez-Carreras, M., Del Hoyo, P., Martín, M. A., Rubio, J. C., Martín, A., Castellano, G., Colina, F., Arenas, J., & Solis-Herruzo, J. A. (2003) · Hepatology · doi:10.1002/hep.1840380426 · Cited by 734 · cited 1×
“A previous study found that hepatic carnitine level was decreased in patients with NASH, which was consistent with a decreased mitochondrial respiratory chain complexes activity and reduced FAO in hepatocytes.(32) Additionally, 2 earlier studies found that carnitine supple-”
Resultγ-Butyrobetaine Is a Proatherogenic Intermediate in Gut Microbial Metabolism of L-Carnitine to TMAO
Koeth, R. A., Levison, B. S., Culley, M. K., Buffa, J. A., Wang, Z., Gregory, J. C., Org, E., Wu, Y., Li, L., Smith, J. D., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.10.006 · Cited by 546
Mechanism of Insulin Resistance in A-ZIP/F-1 Fatless Mice
Kim, J. K., Gavrilova, O., Chen, Y., Reitman, M. L., & Shulman, G. I. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.12.8456 · Cited by 443 · cited 1×
“to increased peripheral lipolysis, uptake of free fatty acid (FFA) and decreased mitochondrial fatty acid oxidation (FAO).(2) NAFLD is a dynamic condition progressing from nonalcoholic fatty liver—simple steatosis—and through increased inflammation, hepatocyte injury, and progressive fibrosis, into nonalcoholic steato…”
BackgroundSelf-citationPrimary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD
Sabino, J., Vieira-Silva, S., Machiels, K., Joossens, M., Falony, G., Ballet, V., Ferrante, M., Van Assche, G., Van der Merwe, S., Vermeire, S., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-311004 · Cited by 413
Li, B., Li, L., Li, M., Lam, S. M., Wang, G., Wu, Y., Zhang, H., Niu, C., Zhang, X., Liu, X., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.02.015 · Cited by 302
Zhang, H.-J., He, J., Pan, L.-L., Ma, Z.-M., Han, C.-K., Chen, C.-S., Chen, Z., Han, H.-W., Chen, S., Sun, Q., et al. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.3202 · Cited by 276 · cited 1×
“Despite its high prevalence and severity, effective treatments for NAFLD progression remain elusive.(3) There is increased evidence supporting the central role of the microbiome in metabolic disorders, with studies trying to elucidate the functional significance of the stool microbiome in the progression of liver dise…”
BackgroundMetabolomic identification of subtypes of nonalcoholic steatohepatitis
Alonso, C., Fernández-Ramos, D., Varela-Rey, M., Martínez-Arranz, I., Navasa, N., Van Liempd, S. M., Lavín Trueba, J. L., Mayo, R., Ilisso, C. P., de Juan, V. G., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.015 · Cited by 263
Lack of mitochondrial trifunctional protein in mice causes neonatal hypoglycemia and sudden death
Ibdah, J. A., Paul, H., Zhao, Y., Binford, S., Salleng, K., Cline, M., Matern, D., Bennett, M. J., Rinaldo, P., & Strauss, A. W. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12590 · Cited by 181
Skagen, K., Trøseid, M., Ueland, T., Holm, S., Abbas, A., Gregersen, I., Kummen, M., Bjerkeli, V., Reier-Nilsen, F., Russell, D., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.01.033 · Cited by 139
Cited by
Gut-liver axis: Pathophysiological concepts and clinical implications
Tilg, H., Adolph, T. E., & Trauner, M. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.09.017 · Cited by 843
Zhang, X., Coker, O. O., Chu, E. S., Fu, K., Lau, H. C. H., Wang, Y.-X., Chan, A. W. H., Wei, H., Yang, X., Sung, J. J. Y., et al. (2021) · Gut · doi:10.1136/gutjnl-2019-319664 · Cited by 841
The gut–liver axis and gut microbiota in health and liver disease
Hsu, C. L., & Schnabl, B. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00904-3 · Cited by 737
Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity
Tilg, H., Adolph, T. E., Dudek, M., & Knolle, P. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00501-9 · Cited by 507
Gut microbiome, liver immunology, and liver diseases
Wang, R., Tang, R., Li, B., Ma, X., Schnabl, B., & Tilg, H. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00592-6 · Cited by 466
Metadata
- Authors
- Zhao, M., Zhao, L., Xiong, X., He, Y., Huang, W., Liu, Z., Ji, L., Pan, B., Guo, X., Wang, L., Cheng, S., Xu, M., Yang, H., Yin, Y., Garcia-Barrio, M. T., Chen, Y. E., Meng, X., & Zheng, L.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 158
- Issue
- 8
- Pages
- 2266-2281.e27
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W3007333206
- Cited by
- 131
- References
- 17
- FWCI
- 5.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.